Intestinal perforation
diseaseOn this page
Also known as bowel perforationperforation of intestine
Summary
Intestinal perforation (MONDO:0006807) is a disease and 19 clinical trials. Top therapeutic interventions include clavulanic acid, amoxicillin, and doripenem. A subtype of intestinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 19
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | intestinal perforation |
| Mondo ID | MONDO:0006807 |
| EFO | EFO:1000987 |
| MeSH | D007416 |
| DOID | DOID:2074 |
| NCIT | C39611 |
| SNOMED CT | 56905009 |
| UMLS | C0021845 |
| MedGen | 9525 |
| MedDRA | 10022694 |
| Is cancer (heuristic) | no |
Also known as: bowel perforation · perforation of intestine
Disease family
This is a subtype of intestinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal perforation
Related subtypes (57): intestinal atresia, steatorrhea, angiodysplasia of intestine, endometriosis of intestine, hypertrophic pyloric stenosis, mucocele of appendix, gastroenteritis, diverticulitis, intestinal obstruction, postgastrectomy syndrome, chronic intestinal vascular insufficiency, bowel dysfunction, irritable bowel syndrome, Whipple disease, inflammatory bowel disease, intestinal polyp, necrotizing enterocolitis, neurogenic bowel, pneumatosis cystoides intestinalis, volvulus of midgut, abetalipoproteinemia, aplasia cutis congenita-intestinal lymphangiectasia syndrome, trichohepatoenteric syndrome, protein-losing enteropathy, chronic diarrhea with villous atrophy, Satoyoshi syndrome, glucose-galactose malabsorption, congenital diarrhea 7 with exudative enteropathy, chronic atrial and intestinal dysrhythmia, congenital enterocyte heparan sulfate deficiency, short bowel syndrome, intractable diarrhea-choanal atresia-eye anomalies syndrome, solitary rectal ulcer syndrome, NK-cell enteropathy, chronic intestinal failure, intestinal lymphangiectasia, refractory celiac disease, eosinophilic gastrointestinal disease, cryptogenic multifocal ulcerous stenosing enteritis, chronic enteropathy associated with SLCO2A1 gene, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, malakoplakia, malabsorption syndrome, ischemic bowel disorder, intestinal neoplasm, intestinal motility disease, 4-hydroxyphenylacetic aciduria, parasitic intestinal disorder, Aeromonas hydrophila intestinal disease, large intestine disorder, small intestine disorder, primary desmosis coli, isolated mesenteric vein thrombosis, collagenous sprue, visceral leiomyopathy, African degenerative, intestinal dysmotility syndrome, intestinal fistula
Subtypes (2): perinatal intestinal perforation, spontaneous intestinal perforation
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07248761 | PHASE4 | ACTIVE_NOT_RECRUITING | Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial |
| NCT01110382 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections |
| NCT01958320 | PHASE2 | COMPLETED | Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus |
| NCT06515405 | Not specified | ACTIVE_NOT_RECRUITING | Effect of Early Hydrocortisone on Risk of Gastrointestinal Perforations in Extremely Preterm Infants |
| NCT06757582 | Not specified | NOT_YET_RECRUITING | Necrotizing Enterocolitis and Bowel Perforation in Very Preterm Infants - Long-term Follow up |
| NCT07429929 | Not specified | NOT_YET_RECRUITING | Saudi Emergency Laparotomy Audit |
| NCT01029353 | Not specified | COMPLETED | Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis |
| NCT01223261 | Not specified | COMPLETED | Observational Study of Surgical Treatment of Necrotizing Enterocolotis |
| NCT01530828 | Not specified | UNKNOWN | IRT in Infants With Intestinal Perforation |
| NCT01784458 | Not specified | COMPLETED | Clinical Significance of Intra-abdominal Hypertension in Surgical Patients With Severe Sepsis |
| NCT02477930 | Not specified | COMPLETED | Endosponge Vacuum Therapy (E-VAC) Registry of Intestinal Anastomotic Leaks and Perforations |
| NCT02679118 | Not specified | COMPLETED | Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery |
| NCT03997721 | Not specified | COMPLETED | Pathophysiology of Perioperative Fluid Management in Emergency Laparotomy |
| NCT04020939 | Not specified | COMPLETED | The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. |
| NCT04180735 | Not specified | COMPLETED | Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital |
| NCT05208489 | Not specified | UNKNOWN | Direct Peritoneal Resuscitation for Intra-abdominal Catastrophes |
| NCT05293353 | Not specified | UNKNOWN | Neokare Safety and Tolerability Assessment in Neonates With GI Problems |
| NCT05562102 | Not specified | UNKNOWN | TyVECO: Surveillance Protocol |
| NCT05734118 | Not specified | UNKNOWN | Safety and Feasibility of Indocyanine Green Fluorescence for Intraoperative Assessment of Intestinal Perfusion in Young Infants and Neonates |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CLAVULANIC ACID | 4 | 3 |
| AMOXICILLIN | 4 | 1 |
| DORIPENEM | 4 | 1 |
| MEROPENEM | 4 | 1 |
Related Atlas pages
- Drugs: Clavulanic Acid, Amoxicillin, Doripenem, Meropenem